Profit finally in sight for gene therapy specialist Oxford Bio – Reuters
|
Profit finally in sight for gene therapy specialist Oxford Bio
Reuters LONDON (Reuters) – After 20 years of losses, gene therapy specialist Oxford BioMedica is at last close to achieving its first profit thanks to the success of Novartis with a pioneering cancer treatment. As manufacturer of the virus-based gene delivery … |
